Generic Drugs Market in Brazil (2007-2011)

Publication Date	December 2007
Publisher	RNCOS
Product Type	Report
Pages	70
ISBN Number	not applicable
Product Code	RCS00196

Price

£750.00
approximately: $1,401 | €951

PDF

PRINT £965 ($1,803 | €1,224)

CD-ROM £965 ($1,803 | €1,224)

Order above formats by FAX

Summary

Brazil, one of the major emerging powers of the world, is marking its presence in almost every dimension of the world economy, including the generic drugs industry. Identifying the importance of the country in this significant domain, the leading market research firm, RNCOS, has come up with research report "Generic Drugs Market in Brazil (2007-2011)" to provide an updated and detailed account of the Brazilian generic drugs industry. It examines the chief reasons why all major generic players are heading to Brazil to manufacture and sell their drugs.

Brazil is currently the largest market for generic drugs in Latin America and with the current scenario and positive future projections, it is likely to emerge amongst the most potential markets for generic drugs in the world.

The generic drugs market in Brazil witnessed an explosive growth of 38.8% and was valued in excess of US$ 1 Billion in 2006. The market was driven by several factors such as a supporting political environment, lower cost and patent expirations of several blockbuster drugs. The market is presently being dominated by domestic generic manufacturers; however, the presence of foreign firms in the market is increasing rapidly.

The growth of the market is expected to remain strong with generics expected to occupy 22.8% of the total market by 2011, enabling Brazil to become one of the largest generic markets in the world. However, despite the strong growth, several challenges still remain to be tackled, including the prevalence of cheaper non-bioequivalent "similar drugs", low prescriptions from the private sector, and low penetration levels in the private sector.

Key Findings

Generics in Brazil occupy nearly 9.5% of the overall pharmaceutical market in terms of sales value.
The domestic generic firms of Brazil are over-dependent on the domestic market and have less participation in foreign markets.
The Brazilian government has made it a norm to prescribe generics in the public sector.
Strengthening of the Brazilian Real has increased the margins of domestic players who import raw materials to manufacture generic drugs. Currently, the domestic industry mainly focuses on finishing generic pharmaceuticals.
One of the biggest opportunities in the generic sector lies in the Antiretroviral segment.
Non-bioequivalent "similar drugs", which are considerably cheaper than generics, are prevalent in the pharmaceutical market.
Cardiovascular diseases are the biggest death cause in Brazil.
Medley and EMS Sigma are the biggest generic manufacturers in Brazil.

Key Issues & Facts Analyzed

Evaluation of past, current and future market trends.
Discussion about the size and growth of the market.
Analysis of healthcare indicators.
Future prospects of the generics market.
Analysis of various challenges and opportunities before the industry.
Profile discussion of key players in this sector.

Key Players Analyzed

This section provides the overview, key facts, and financial information of prominent players in the Brazil Generics Market, such as Medley, EMS Sigma Pharma, Eurofarma Laboratorios Ltd, Ach Pharmaceutical Laboratories S/A and Ranbaxy.

Research Methodology Used

Information Sources

The information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and over 3000 paid databases.

Analysis Methods

The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.

Content

1. Analyst View
2. Global Generic Drugs Market
- 2.1 Market Size & Growth
- 2.2 Geographical Performance
3. Brazil Demographics & Healthcare Profile
- 3.1 Demographics & Macroeconomic Indicators
  - 3.1.1 Macroeconomic Indicators
  - 3.1.2 Population
  - 3.1.3 Life Expectancy
  - 3.1.4 Infant Mortality Rate
  - 3.1.5 Age Breakup
- 3.2 Healthcare Indicators
  - 3.2.1 Healthcare Structure
  - 3.2.2 Doctors & Hospital Beds
  - 3.2.3 Healthcare Expenditure
  - 3.2.4 Main Causes of Death
4. Brazil Pharmaceutical Market
- 4.1 Industry Performance
  - 4.1.1 Drug Categories
  - 4.1.2 Market Size & Growth
    - 4.1.2.1 Sales Value
    - 4.1.2.2 Sales Volume
  - 4.1.3 Private & Public Market
  - 4.1.4 Import & Export
  - 4.1.5 Major Pharmaceutical Segments
  - 4.1.6 Investments
  - 4.1.7 Performance of Key Players
5. Brazil Generic Drugs Market
- 5.1 Market Drivers
  - 5.1.1 Low Cost
  - 5.1.2 Strong Investment
  - 5.1.3 Strong Government Support
  - 5.1.4 Patent Expiries
  - 5.1.5 Ageing Population
  - 5.1.6 Strengthening of Real
  - 5.1.7 Increasing Prescription Rates
- 5.2 Industry Performance
  - 5.2.1 Market Size & Growth
    - 5.2.1.1 Sales Value
    - 5.2.1.2 Sales Volume
  - 5.2.2 Regulatory Environment
  - 5.2.3 Investments
  - 5.2.4 Performance of Key Players
- 5.3 Restraints
  - 5.3.1 Dependence on Imported Raw Materials
  - 5.3.2 Over-reliance of Domestic Generic Firms on Domestic Market
  - 5.3.3 Lack of Awareness & Low Prescriptions in Private Sector
  - 5.3.4 Prevalence of 'Similar Drugs'
  - 5.3.5 Counterfeit Drugs
- 5.4 Promising Segments in the Generic Business
  - 5.4.1 Antiretroviral
  - 5.4.2 Oral Contraceptives
  - 5.4.3 Erectile Dysfunction
  - 5.4.4 Anti-Thrombotics
  - 5.4.5 Cardiovascular Drugs
  - 5.4.6 Anti-diabetics
6. Future Outlook (2007-2011)
- 6.1 Pharmaceutical Market
- 6.2 Generic Drugs Market
7. Profiles of Key Players
- 7.1 EMS Sigma Pharma
- 7.2 Medley
- 7.3 Eurofarma Laboratorios Ltda
- 7.4 Ach Pharmaceutical Laboratories S/A
- 7.5 Ranbaxy
List of Tables:
- Table 4-1: Brazil - Performance of Top 10 Players in Pharmaceutical Market, 2006
- Table 5-1: Brazil - Patent Expiry & Sales of Key Drugs
- Table 5-2: Brazil - Performance of Top Players in Generic Drugs Market (2005 & 2006)
- Table 5-3: Brazil - Erectile Dysfunction Market (in Million BRL), 2005 & 2006
- Table 5-4: Brazil - Diabetic Patients in Age Group 20-79 (in '000), 2003
- Table 5-5: Brazil - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
- Figure 2-1: Global - Pharmaceutical Market (in Billion US$), 1999-2006
- Figure 2-2: Global - Generic Drugs Market (in Billion US$), 2001-2006
- Figure 2-3: Global - Revenues of Top 3 Generic Companies (in Billion US$), 2006
- Figure 2-4: Global - Forecast for Generic Drugs Market (in Billion US$), 2007-2011
- Figure 2-5: Global - Share of Generic Drugs in Pharmaceutical Market (%), 2006 & 2011F
- Figure 2-6: Global - Generic Drugs Market by Region (%), 2006
- Figure 2-7: Brazil & Global - Growth Rate of the Generic Drugs Market (%), 2006
- Figure 3-1: Brazil - Nominal GDP (in Trillion BRL) 2001-2006
- Figure 3-2: Brazil - Consumer Price Index (%), 2001-2006
- Figure 3-3: Brazil - Currency Exchange Rates (From US$ to BRL), 2001-2006
- Figure 3-4: Brazil - Foreign Direct Investment (in Billion US$), 2004-2006
- Figure 3-5: Brazil - Population (in Million), 2001-2006E
- Figure 3-6: Brazil - Life Expectancy of Male & Female (in Years), 2001-2006E
- Figure 3-7: Brazil - Infant Mortality Rate (per '000 Live Births), 2001-2006E
- Figure 3-8: Brazil - Population Breakup by Age (%), 2001-2006E
- Figure 3-9: Brazil - Number of Doctors (per '000 Population), 2001-2006E
- Figure 3-10: Brazil - Number of Hospital Beds (per '000 Population), 2002 & 2003E
- Figure 3-11: Brazil - Share of Healthcare Expenditure in GDP (%), 2001-2006E
- Figure 3-12: Brazil - Per Capita Healthcare Expenditure (in US$), 2001-2006E
- Figure 3-13: Brazil - Main Causes of Death (%), 2005E
- Figure 3-14: Brazil - Main Causes of Death (%), 2030F
- Figure 4-1: Brazil - Pharmaceutical Market Sales Value (in Billion BRL), 2001, 2002E & 2004-2006
- Figure 4-2: Brazil - Pharmaceutical Market Sales Value (in Billion US$), 2001, 2002E & 2004-2006
- Figure 4-3: Brazil - Pharmaceutical Market Sales Volume (in Billion Units), 2004-2006
- Figure 4-4: Brazil - Share of Public & Private Pharmaceutical Market (%), 2006
- Figure 4-5: Brazil - Private Pharmaceutical Market (in Billion BRL), 2004-2006
- Figure 4-6: Brazil - Public Pharmaceutical Market (in Billion BRL), 2004-2006
- Figure 4-7: Brazil - Pharmaceutical Exports Sales Value (in Million US$), 2004-2007F
- Figure 4-8: Brazil - Pharmaceutical Exports Sales Volume (in Tons) 2004-2007F
- Figure 4-9: Brazil - Pharmaceutical Imports Sales Value (in Billion US$), 2004-2007F
- Figure 4-10: Brazil - Pharmaceutical Imports Sales Volume (in Tons), 2004-2007F
- Figure 4-11: Brazil - Pharmaceutical Trade Deficit (in Million US$), 2004-2007F
- Figure 4-12: Brazil - Share of Major Segments of Pharmaceutical Market (%), 2006*
- Figure 4-13: Brazil - Pharmaceutical Investments (in Billion BRL), 2006 & 2007E
- Figure 4-14: Brazil - Share of Investment in Various Pharmaceutical Segments (%), 2007E
- Figure 5-1: Brazil - Price Comparison of Medley's Generic Version of Plenty with its Branded Version (in BRL), 2006
- Figure 5-2: Brazil - Population above 65 Years (%), 2001-2006E
- Figure 5-3: Brazil - Share of Prescriptions for Branded & Generic Drugs in Pharmaceutical Market (%), 2005 & 2006
- Figure 5-4: Brazil - Share of Prescriptions for Atenolol, Cephalexin & Omeprazol in Branded & Generic Drugs Prescriptions (%), April 2006
- Figure 5-5: Brazil - Share (Sales Value) of Generic Drugs in Pharmaceutical Market (%), 2006
- Figure 5-6: Brazil - Generic Drugs Sales Value (in Million US$), 2004-2006
- Figure 5-7: Brazil - Growth Rate of Generic Drugs Sales Value (%), 2005 & 2006
- Figure 5-8: Brazil - Generic Drugs Sales Value (in Million US$), H1 2006 & H1 2007
- Figure 5-9: Brazil - Share (Sales Volume) of Generic Drugs in Pharmaceutical Market (%), 2006
- Figure 5-10: Brazil - Generic Drug Sales Volume (in Million Units), 2004-2006
- Figure 5-11: Brazil - Generic Drugs Sales Volume (in Million Units), H1 2006 & H1 2007
- Figure 5-12: Brazil - Investment in Generic Drugs (in Million US$), 2000-2006 & 2007-2011F
- Figure 5-13: Brazil - Breakup of Investment in Generic Drugs Market (%), 2007 to 2011
- Figure 5-14: Brazil - Number of Companies Manufacturing Generic Drugs (2000 & 2006)
- Figure 5-15: Brazil - Share of Top Players in Generic Drugs Market (%), 2006
- Figure 5-16: Brazil - Share of Imported & Locally Produced Raw Materials (%), 2006
- Figure 5-17: Brazil - Number of HIV Patients* & HIV Patients on Anti-Retroviral Therapy (in '000), 2006
- Figure 5-18: Brazil - Share of Top Players in Oral Contraceptives Market (%), 2006
- Figure 5-19: Brazil - Share of Top Players in Erectile Dysfunction Market (%), Nov 2006
- Figure 5-20: Brazil - Deaths from Cardiovascular Diseases (%), 2005 & 2030F
- Figure 5-21: Brazil - Cardiovasular Drugs Market (in Million US$), 2005 & 2006
- Figure 5-22: Brazil - Insulin Market (in Million US$), 2000, 2006 & 2010F
- Figure 6-1: Brazil - Forecast for Pharmaceutical Market (in Billion US$), 2007-2011
- Figure 6-2: Brazil - Forecast for Generic Drugs Market (in Billion US$), 2007-2011
- Figure 6-3: Brazil - Contribution of Generic & Non-Generics in Growth of Pharmaceutical Market (%), 2006-2011
- Figure 6-4: Brazil - Forecast for Share of Generic Drugs in Pharmaceutical Market (%), 2007-2011